Maxcyte, Inc. (MXCT) Stock Price & Analysis
Maxcyte, Inc. (MXCT) fell 3.57% to USD 1.08 as of July 25, 2026 at 06:39 UTC, according to Nexqual real-time market data.
MXCT last closed at USD 1.12; the session ranged USD 1.07–1.13 on volume of 504,626 shares. Market capitalization is $115.69M, with a 52-week range of USD 0.64–2.31 (NMS). Source: Nexqual, July 25, 2026 at 06:39 UTC.
Key Statistics (as of July 25, 2026 at 06:39 UTC)
| Price | USD 1.08 |
|---|---|
| Change | ▼ 3.57% (down) |
| Previous Close | USD 1.12 |
| Open | USD 1.12 |
| Day Range | USD 1.07 – 1.13 |
| 52-Week Range | USD 0.64 – 2.31 |
| Volume | 504,626 shares |
| Market Cap | $115.69M |
| Exchange | NMS |
Technical Analysis (MXCT)
Nexqual's technical model rates MXCT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:39 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 37.15 (neutral) |
| vs SMA50 | Below (USD 1.18) |
| MACD | -0.01 (negative) |
Analyst Ratings (MXCT)
Wall Street analysts rate MXCT "Strong Buy" based on 4 analysts, with a mean price target of USD 4.11 (range USD 2.43–5), per Nexqual as of July 25, 2026 at 06:39 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 4.11 |
| High Target | USD 5 |
| Low Target | USD 2.43 |
| Buy / Hold / Sell | 5 / 1 / 0 |
Earnings (MXCT)
| Next Earnings Date | 2026-08-12 |
|---|---|
| EPS Estimate | USD -0.09 |
| Revenue Estimate | $6.47M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.06 vs est -0.08 ▲ beat |
| 2025-09-30 | USD -0.09 vs est -0.1 ▲ beat |
| 2025-06-30 | USD -0.12 vs est -0.1 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Financials & Fundamentals (MXCT)
| Total Revenue | $32.29M |
|---|---|
| Revenue Growth (YoY) | -7.10% |
| Gross Margin | +80.51% |
| Operating Margin | -64.09% |
| Profit Margin | -121.16% |
| ROE | -21.30% |
| Debt / Equity | 10.42 |
| Current Ratio | 12.04 |
| Total Cash | $106.85M |
| Total Debt | $17.49M |
| Free Cash Flow | $-14.13M |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Financial Health Score (MXCT)
Nexqual rates Maxcyte, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:39 UTC.
| Growth | Critical — Revenue -15% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $107M cash vs $17M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$14M, burning cash |
| Efficiency | Critical — ROE -21%, ROA -11.3% |
Ownership (MXCT)
| Insider Ownership | +1.59% |
|---|---|
| Institutional Ownership | +68.02% |
| Shares Outstanding | 107.12M |
| Float | 97.63M |
| Short % of Float | +1.33% |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
Leadership (MXCT)
Maxcyte, Inc. is led by Maher Masoud (age 49), President, CEO & Executive Director, per Nexqual as of July 25, 2026 at 06:39 UTC.
| President, CEO & Executive Director | Maher Masoud (age 49) |
|---|---|
| Chief Financial Officer | Parmeet Ahuja (age 56) |
| Senior Vice President of Corporate Development | Jack Horgan |
| Senior Vice President of Global Sales | Ana-Paula Martins Fernandes |
| Senior Vice President of Human Resources | Jill Mayer |
Major Backers & Investors (MXCT)
Notable institutional backers of Maxcyte, Inc. include Capricorn Fund Managers Ltd, Vitruvian Partners, LLP, Morgan Stanley, according to Nexqual as of July 25, 2026 at 06:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Capricorn Fund Managers Ltd | 7.65% |
| Vitruvian Partners, LLP | 4.71% |
| Morgan Stanley | 3.76% |
| Mudita Advisors LLP | 3.15% |
| BNP Paribas Asset Management Holding S.A. | 2.59% |
| Brooklands Fund Management Ltd | 2.04% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 11.56% |
| Vanguard Group | 8.12% |
| Geode Capital | 2.21% |
| State Street | 2.05% |
Source: Nexqual, July 25, 2026 at 06:39 UTC.
From Maxcyte, Inc.'s Latest SEC 10-K Filing (filed 2026-03-25)
Key Strengths & Strategy (as disclosed to the SEC)
- To date, our FDA Master File and Technical Files have been referenced by our customers in over 75 clinical trials. 10 Table of Contents Our Technology Platform The foundation of our technology platform is our proprietary and patented Flow Electroporation technology, which we have developed and optimized for more than 25 years.
- In order to support our customers' use of our platform in regulatory submissions, we have submitted Master Files to the FDA, Center for Biologics Evaluation and Research and Master Files and/or Technical Files to comparable regulatory authorities in other jurisdictions, including Canada, Japan, Australia, the United Kingdom and Austria, and provide nonexclusive Letters of Authorization to the Master or Technical Files under contractual agreements with our customers.
- Over more than two decades, we have developed and commercialized our proprietary Flow Electroporation ® technology, which is used by biopharmaceutical companies in the complex engineering of a wide variety of cells.
- Our proprietary Flow Electroporation platform is fully scalable and can support small-scale research and development and manufacturing through large-scale cell engineering for development of commercial therapeutics. ​ Our technology platform is marketed under the ExPERT brand, the elements of which are depicted in the graphic above.
Partnerships
- Annual instrument license fees are non-refundable and customers may not use our instruments or process assemblies after terminating their agreement with us.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CTKB | Cytek Biosciences, Inc. | USD 4.46 | ▼ 1.76% |
| SGHT | Sight Sciences, Inc. | USD 4.91 | ▼ 2.39% |
| TMCI | Treace Medical Concepts, Inc. | USD 4 | ▲ 0.76% |
| CRBU | Caribou Biosciences, Inc. | USD 1.57 | ▼ 5.42% |
| RLYB | Rallybio Corporation | USD 16.31 | ▼ 1.87% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:39 UTC. This page is informational and not investment advice.